Status:
ACTIVE_NOT_RECRUITING
Long-term Outcomes of Prostate Cancer Screening
Lead Sponsor:
Karolinska Institutet
Collaborating Sponsors:
Swedish Cancer Foundation
The Swedish Research Council
Conditions:
Prostate Cancer
Eligibility:
MALE
50-74 years
Phase:
NA
Brief Summary
This study is an expansion of the screening-by-invitation STHLM3MRI trial for detection of prostate cancer. In summary, we assess longterm outcomes (prostate cancer mortality, incidence and resource u...
Eligibility Criteria
Inclusion
- Eligible participants:
- Men eligible for the longterm f/u-study arms (experimental and control) are participants in the STHLM3MRI trial.
- Men age 50-74 years without prior diagnosis of prostate cancer (ICD-9 C61).
- Permanent postal address in Stockholm
- Not a previous participant in the Stockholm3 study (2012-2014)
Exclusion
- Severe illnesses such as metastatic cancers, severe cardio-vascular disease or dementia
- Contraindications for magnetic resonance imaging (MRI) eg pacemaker, magnetic cerebral clips, cochlear implants or severe claustrophobia.
- Men with a previous prostate biopsy the preceding 60 days before invitation.
Key Trial Info
Start Date :
November 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2035
Estimated Enrollment :
7500 Patients enrolled
Trial Details
Trial ID
NCT07155759
Start Date
November 1 2024
End Date
November 1 2035
Last Update
September 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Karolinska Institutet
Stockholm, Sweden